
cs @uwaterloo, prev @datacurve @menloresearch | 🏃♂️🫀 ✝️
🇸🇬/🇨🇦/🇺🇸
Joined June 2021
- Tweets1.7K
- Following1.1K
- Followers980
- Likes13.6K
All university rankings are very flawed.
I wondered how we could rank unis as purely as possible? So I looked at the career path of ~100,000 engineers over 10yrs. Universities rank high when its graduates work at companies, ranked PageRank style, that engineers compete harder to join.
Stanford, MIT, Harvard were top 3, but the extent they were above the rest surprised me. Brown at #6, Waterloo at #7!
Daniel Ching retweeted
Asimov 1 is an open-source humanoid robot you can build, train, and customize.
- 1.2 m tall, 35 kg
- 25 powered joints
- Open hardware with off-the-shelf parts
- Open-source SDK and simulation models
Available as a DIY kit.
Order yours at menlo.ai/order
Daniel Ching retweeted
one of my favorite projects from this summer :)
Everyone thinks computer use agents are the future in healthcare, but you can't just let agents run amok in EHRs without any guardrails.
Our summer intern, @shayaan_azeem, took a better approach: he created a system for agents to build EHR browser automations without ever letting one act unsupervised in prod.
Shayaan was an awesome intern this summer, and it was a blast watching him build this.
Here's the full write-up: build.forus.com/ehr-browser-…
Daniel Ching retweeted
in April, we published a launch essay for @tacitlabsco
that outlined a thesis for frontier AI research in biology -
1. if we want models to be useful for curing disease, we must evaluate them on tasks with roughly that shape and complexity. optimize directly on the thing you care about - i.e. discovering & developing a drug
2. we should aim to model the biotech (process, reasoning, decision-making), rather than the underlying biology. biology is an empirical science - develop better empirical methods rather than treating it as an analytical domain
3. the most difficult part of all of this will be verification of those empirical methods with signal that actually matters (does the proposed drug actually work in a human?). biological time is a tough wall to run up against (most expensive forward-pass of all time). figuring out how to turn scientific problems into learning problems is a first-class research problem
4. if we believe (1) and (2), and we do a bunch of good work and figure out some clever solutions to (3) then we unlock increasingly agentic discovery/development, with the logical extreme being this concept of the "zero-person biotech", which is now (somehow) percolating in mainstream discourse
5. (4) has extremely exciting implications for the overall economics and practicalities of how we develop novel therapeutics (broadening viable aperture to rare disease, n-of-1 trials; new mechanisms of distribution) all of which are net positive for the world. much to be optimistic on here
discovering and developing a drug is one of the most complex and long-horizon tasks in the broad spectrum of human endeavors. inarguably one of the most important and high-impact research directions in AI today
I trained a 750K-parameter world-model agent on my M5 Pro to play video games!
Presenting NanoDreamer: a tiny Dreamer-inspired agent that learns game dynamics and trains an actor–critic in latent imagination.
Write-up: benjamin-bai.com/projects/na…
Daniel Ching retweeted
What still limits a sub-2 marathon? And could a second fuel move it?
I wrote a technical analysis on running economy, durability and exogenous lactate. It has more questions than answers, on purpose. 🧵
Daniel Ching retweeted
i get asked VERY frequently to chat about data / RL envs / new companies coming into the space. all of the questions tend to be exactly the same so i want to summarize my thoughts:
Q: "Should I start a data company?"
A: probably not, unless you have some sort of alpha or have seen what frontier RL envs are like. basically, if you're not deep within an industry, seen data via a lab or working at another data company, or very well connected with lab researchers, you probably should not. though, if its your passion, now is the best time and it'll get increasingly worse. data is also much harder now than it was 6 months ago, and quality standards are ever-increasing.
Q: "Is there a product in the space?"
A: i think there are repeatable systems that can be created. i.e. QA systems, faster task generation, infrastructure around rollouts/VMs/GPU utilization/prod. system emulation etc. i think data is inherently bespoke, luckily LLMs allow you to harness bespoke intellect infinitely. i don't think it's a SaaS style product where it serves everyone immediately, but more of a quant-desk type system with alpha on how to do specific tasks embedded within an engineer-system like manner. each eng will have a desk that serves them specifically that unlocks 10x, 100x, 1000x capabilities.
Q: "Is {insert set} data valuable"
A: depends on what you do with it. raw data dumps are cool but it's a lot more about what you can turn it into.
Q: "How does {insert data company} differ from {insert competitor}?"
OR
"Should I join {insert data company}?"
A: if you're in the "big, legacy" data companies with contractors, it doesn't really differ that much. if i had to pick, i'd probably join mercor or surge from the big contractor companies, by virtue of early employees/founders being extremely smart. however, i'd much rather join a small, research-heavy data company. they are by far the companies with the highest slope.
Q: "Won't labs just in-house this anyway?"
A: (1) data is an additive game that isn't zero-sum. just because labs are increasing synthetic data creation internally does not mean they won't buy more data. especially given it is an arms race to the top of intellect, if you can just make valuable data that moves the needle, it doesn't really matter if they can replicate it, it's not worth their researcher time if you solve a problem. the caveat being you have to actually add something yourself, and not just be a parrot who takes requests. saving researcher time is the name of the game.
(2) i think this logic applies to everything, if you adopt this mentality, you probably should not work at any applied AI company, since they'll come after or absorb most products in the space.
Daniel Ching retweeted
Biology lags code by about a year. But there are strong + unintuitive technical parallels.
Daniel Ching retweeted
as a runner, moving to SF meant improvising a run (as I often did in London/Santa Monica) could send me up a small mountain ... so I built: flattensf.com
Daniel Ching retweeted
Replying to @SaladCoInc
@SaladCoInc will be presenting LakeQuest tomorrow at COLM - come find us!
Paper #1073 poster session: Poster 1 (Tuesday Morning 11am)
Poster room: Franciscan
Poster number: F-1-135
Daniel Ching retweeted
I am at COLM until Friday - please email/find me if you’d like to chat about grad school or faculty jobs at Waterloo! The R2L lab will be looking for 1-2 PhD students, please see r2llab.com
Last week, I joined @PrimeIntellect as an intern to help optimize their inference stack :)
Very grateful to get the chance to work with such a talented team of researchers and engineers
Plenty to do and much to learn, super excited for what’s ahead!
Daniel Ching retweeted
it's unfortunate that most people don't spend time reading agent traces via evals to understand the major pitfalls of agents. there are leaps and bounds of model capabilities left to learn if you know where to look.
Daniel Ching retweeted
Can you really trust an AI's legal advice?
I partnered with Legal Benchmarks @aguozy to launch their new leaderboard measuring frontier legal capabilities.
Here's how we built the task environment and calibrated an LLM judge against lawyer preferences. 👇
Daniel Ching retweeted
the past few months of growth have been insane to watch up close.
i joined in april and spent my summer building agents to get patients medicine, cheaper, faster and easier.
today forus is a $3b company, and only getting started. so proud of this team!
We’re announcing that Forus has raised a $150M Series C at a $3B valuation to build the AI network for medicine.
Medicine will remain one of the world’s most important industries until humanity achieves immortality, and we are only at the beginning of a new era in what it can do. GLP-1s are changing obesity and cardiometabolic disease. Gene therapies can treat diseases at their genetic source. New cancer treatments are turning diagnoses that were once fatal into diseases people can live with. AI is enabling us to discover of new drugs even faster.
But discovery is only the beginning. It still takes more than a decade and billions of dollars to turn a new molecule into an approved medicine, and once it reaches market, more than a third of patients prescribed specialty treatments never receive their first dose.
Forus is creating the AI network to accelerate the entire medicine pipeline, from development and launch through prescription and treatment. We connect the companies creating medicines with the doctors who prescribe them and the patients who need them.
Today, Forus supports millions of people across all 50 states and is already used by providers to treat patients in 85% of U.S. residential ZIP codes. 9 of the top 15 global biopharma companies work with us, alongside many fast-growing biotechs. Our goal is to put Forus in every doctor’s office in the country and unlock an order of magnitude more medicine for society.
There is a generational opportunity to rethink how new medicine reaches people. Forus is becoming how medicine moves from discovery to treatment in America, and as we scale, we’ll become the most important company in life sciences.
Forus is not constrained by capital or customer demand; we are constrained by the talent and capacity of our team. To take on the opportunity in front of us, we need exceptional engineers and operators in New York who want to move fast and help us make something that matters. Come build with us.
Our Series C was led by Bain Capital Ventures, with Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel investing alongside them.
Daniel Ching retweeted
What is the cost of 1 F-35 fighter in terms of the # of OG Rubin Ultra 1024GB HBM vs. the new Rubin "Ultra" 192GB HBM?
Daniel Ching retweeted
What's the best predictor of world-class performance in runners?
Volume of Training.
You've got to spend a lot of time doing the thing if you want to get good at just about anything.
































